View Item 

Show simple item record

Liver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis
dc.contributor.authorKim, Hannah P.
dc.contributor.authorIdowu, Michael O.
dc.contributor.authorMospan, Andrea R.
dc.contributor.authorAllmon, Andrew G.
dc.contributor.authorRoden, Michael
dc.contributor.authorNewsome, Philip
dc.contributor.authorLok, Anna S.
dc.contributor.authorThuluvath, Paul J.
dc.contributor.authorTaunk, Jawahar
dc.contributor.authorFried, Michael W.
dc.contributor.authorSanyal, Arun J.
dc.contributor.authorBarritt, A. Sidney
dc.contributor.authorAbdelmalek, Manal
dc.date.accessioned2021-12-02T02:28:21Z
dc.date.available2023-01-01 21:28:21en
dc.date.available2021-12-02T02:28:21Z
dc.date.issued2021-12
dc.identifier.citationKim, Hannah P.; Idowu, Michael O.; Mospan, Andrea R.; Allmon, Andrew G.; Roden, Michael; Newsome, Philip; Lok, Anna S.; Thuluvath, Paul J.; Taunk, Jawahar; Fried, Michael W.; Sanyal, Arun J.; Barritt, A. Sidney; Abdelmalek, Manal (2021). "Liver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis." Alimentary Pharmacology & Therapeutics (11-12): 1472-1480.
dc.identifier.issn0269-2813
dc.identifier.issn1365-2036
dc.identifier.urihttps://hdl.handle.net/2027.42/170951
dc.publisherWiley Periodicals, Inc.
dc.titleLiver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/170951/1/apt16674_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/170951/2/apt16674.pdf
dc.identifier.doi10.1111/apt.16674
dc.identifier.sourceAlimentary Pharmacology & Therapeutics
dc.identifier.citedreferenceBarritt AS, Gitlin N, Klein S, et al. Design and rationale for a real‐world observational cohort of patients with nonalcoholic fatty liver disease: the TARGET‐NASH study. Contemp Clin Trials. 2017; 61: 33 ‐ 38.
dc.identifier.citedreferenceLazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988–1994. Am J Epidemiol. 2013; 178: 38 ‐ 45.
dc.identifier.citedreferenceRinella ME. Nonalcoholic fatty liver disease a systematic review. J Am Med Assoc. 2015; 313: 2263 ‐ 2273.
dc.identifier.citedreferenceDulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta‐analysis. Hepatology. 2017; 65: 1557 ‐ 1565.
dc.identifier.citedreferenceYounossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64: 73 ‐ 84.
dc.identifier.citedreferenceYounossi Z, Henry L. Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver‐related morbidity and mortality. Gastroenterology. 2016; 150: 1778 ‐ 1785.
dc.identifier.citedreferenceChalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67: 328 ‐ 357.
dc.identifier.citedreferenceCataldo I, Sarcognato S, Sacchi D, et al. Pathology of non‐alcoholic fatty liver disease. Pathologica. 2021; 113: 194 ‐ 202.
dc.identifier.citedreferenceKobyliak N, Abenavoli L. The role of liver biopsy to assess non‐alcoholic fatty liver disease. Rev Recent Clin Trials. 2015; 9: 159 ‐ 169.
dc.identifier.citedreferenceRinella ME, Tacke F, Sanyal AJ, Anstee QM. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. J Hepatol. 2019; 71: 823 ‐ 833.
dc.identifier.citedreferenceCheung A, Neuschwander‐Tetri BA, Kleiner DE, et al. Defining improvement in nonalcoholic steatohepatitis for treatment trial endpoints: recommendations from the liver forum. Hepatology. 2019; 70: 1841 ‐ 1855.
dc.identifier.citedreferenceSanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011; 54: 344 ‐ 353.
dc.identifier.citedreferenceKalambokis G, Manousou P, Vibhakorn S, et al. Transjugular liver biopsy – indications, adequacy, quality of specimens, and complications – a systematic review. J Hepatol. 2007; 47: 284 ‐ 292.
dc.identifier.citedreferenceMyers RP, Fong A, Shaheen AAM. Utilization rates, complications and costs of percutaneous liver biopsy: a population‐based study including 4275 biopsies. Liver Int. 2008; 28: 705 ‐ 712.
dc.identifier.citedreferencePiazzolla VA, Mangia A. Noninvasive diagnosis of NAFLD and NASH. Cells. 2020; 9: 1005.
dc.identifier.citedreferenceCastera L, Friedrich‐Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019; 156: 1264 ‐ 1281.e4.
dc.identifier.citedreferenceBarritt AS, Watkins S, Gitlin N, et al. Patient determinants for histologic diagnosis of nonalcoholic fatty liver disease in the real world: a TARGET‐NASH study. Hepatol Commun. 2021; 5: 938 ‐ 946.
dc.identifier.citedreferenceMalespin MH, Barritt AS, Watkins SE, et al. Weight loss and weight regain in usual clinical practice: results from the TARGET‐NASH observational cohort. Clin Gastroenterol Hepatol 2021;S1542‐3565(21)00073‐2. Online ahead of print.
dc.identifier.citedreferenceMoon AM, Watkins SE, Lok AS, et al. Opioid use is more common in non‐alcoholic fatty liver disease patients with cirrhosis, higher body mass index and psychiatric disease. Dig Dis. 2020; 39: 247 ‐ 257. Online ahead of print.
dc.identifier.citedreferenceWeinberg EM, Trinh HN, Firpi RJ, et al. Lean Americans with nonalcoholic fatty liver disease have lower rates of cirrhosis and comorbid diseases. Clin Gastroenterol Hepatol. 2021; 19: 996 ‐ 1008.e6.
dc.identifier.citedreferenceKleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41: 1313 ‐ 1321.
dc.identifier.citedreferenceBrunt EM, Janney CG, Di Bisceglie AM, Neuschwander‐Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999; 94: 2467 ‐ 2474.
dc.identifier.citedreferenceRatziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005; 128: 1898 ‐ 1906.
dc.identifier.citedreferenceLandis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977; 33: 159 ‐ 174.
dc.identifier.citedreferenceBrunt EM, Kleiner DE, Carpenter DH, et al. Nonalcoholic fatty liver disease: reporting histologic findings in clinical practice. Hepatology. 2021; 73: 2028 ‐ 2038.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
apt16674_am.pdf
Size:
315.8KB
Format:
PDF
View/Open
Name:
apt16674.pdf
Size:
560.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.